

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.			
10/677,977	10/02/2003	Jack Nguyen	19049-005001 / 4905	9061			
20985 FISH & RICHA	7590 10/16/2007 ARDSON PC		EXAM	INER			
P.O. BOX 1022		WESSENDORF, TERESA D					
MINNEAPOLI	S, MN 55440-1022		ART UNIT	PAPER NUMBER			
			1639				
			MAIL DATE	DELIVERY MODE			
			10/16/2007	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



# UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO./
CONTROL NO.

FILING DATE

FIRST NAMED INVENTOR I
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

10677977

10/2/2003

NGUYEN ET AL.

19049-005001 / 4905

.1

Ä,

.)

FISH & RICHARDSON, PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022 EXAMINER

T. D.. Wessendorf

ART UNIT

PAPER

1639

5

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. See attached errors in sequence listing. Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply. Any inquiry concerning this communication or earlier communications from the examiner should be directed to T. D. Wessendorf whose telephone number is (571) 272-0812. The examiner can normally be reached on Flexitime. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Schultz can be reached on 571 272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect uspto gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

> T. D. Wessendort Primary Examiner Art Unit: 1639

> > 10/15/87

----

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)

217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Wed Sep 05 15:35:32 EDT 2007

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer Comments:

<210> 6

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> Variant

<222> (1)..(1)

<223> Wherein Xaa is an N-acetyl group.

<220>

<221> Variant

<222> (6)..(6)

<223> Wherein Xaa is a 7-amino-4-methylcoumarin group.

<400> 6

Xaa Ile Glu Pro Asp Xaa

1

5

The above explanations for Xaa are invalid: "Xaa" can only represent a single amino acid, not a functional group.

<210> 29

<211> 4

<212> PRT

<213> Homo sapiens

```
<220>
<223> Chymotrypsin substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa= Val or Pro
<220>
<221> VARIANT
<222> 4
<223> Xaa= Phe ot Tyr
<400> 29
Xaa Xaa Xaa Xaa
 1
The above <223> explanation for "Xaa" at location 4 contains a
misspelling: please replace "ot" with "or."
<210> 54
<211> 4
<212> PRT
<213> Homo sapiens
```

<220>

<223> Cathepsin F substrate spec.

```
<221> VARIANT
```

<222> 1

<223> Xaa=any amino acid

<220>

<221> VARIANT

<222> 3

<223> Xaa=any amino acid

<220>

<221> VARIANT

<222> 4

<223> Xaa=Lys or Arg

<400> 54

Xaa Xaa Leu Xaa

1

The above " $\langle 222 \rangle$  3" is an incorrect location for "Xaa:" "Leu" is at location 3; "Xaa" is at location 2.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

### Validated By CRFValidator v 1.0.3

Application No:

10677977

Version No:

4.0

. ;

. !

.)

.1

 $r_{\rm c}$ 

Input Set:

Output Set:

**Started:** 2007-08-23 14:48:11.063

Finished: 2007-08-23 14:48:11.915

**Elapsed:** 0 hr(s) 0 min(s) 0 sec(s) 852 ms

Total Warnings: 3

Total Errors: 3

No. of SeqIDs Defined: 57

Actual SeqID Count: 57

Err	or code	Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
. W	213	Artificial or Unknown found in <213> in SEQ ID (5)
W	213	Artificial or Unknown found in <213> in SEQ ID (22)
Е	257	Invalid sequence data feature in <221> in SEQ ID (22)
Ē	257	Invalid sequence data feature in <221> in SEQ ID (22)
E	341	'Xaa' position not defined SEQID (54) POS (2)

#### SEQUENCE LISTING

<110		Nguye Thand Waugh Crai)	os, ( n Rug	Chri:	s, Sá		a										
<120		METHO SPECI			ENER!	MITA	3 ANI	SCI	REEN	ING I	FOR 1	PROTI	EASE:	S WIT	ГН А	LTER	ED
<130	)>	19049	9-00	5001,	/4905	5											
<140	)>	1067	7977														
<141	.>	2003-	-10-0	02													
<150	)>	60/42	25,38	38													
<151	•	2002-															
											٠.						
<160	)>	57															
<170	)>	FastS	SEQ 1	for V	Vindo	ows <sup>7</sup>	/ers:	ion 4	4.0								
<210	١>	1															
<211		1 277															
<212		PRT									•						
<213	3>	Homo	sap:	iens													
<400	)>	1															
	Glu	Asn	Thr		Asn	Ser	Val	Asp		Lys	Ser	Ile	Lys	Asn	Leu	ı	
1				5					10					15			
•																	
Glu	Pro	Lys	Tle	Tle	His	Glv	Ser	Glu	Ser	Met	Asp	Ser	Glv	Tle	Ser		
		-1-	20			017		25	001		p	501	30		001		
Leu	Asp	Asn	Ser	Tyr	Lys	Met	Asp	Tyr	Pro	Glu	Met	Gly	Leu	Суз	Ile		
		35					40					45					
Ile	Tle	Asn	Asn	Lvs	Asn	Phe	His	Lvs	Ser	Thr	Glv	Met	Thr	Ser	Ara	r	
	50			_10		55		_,_	501		60			501		,	
							•										
	Gly	Thr	Asp	Val	Asp	Ala	Ala	Asn	Leu	Arg	Glu	Thr	Phe	Àrg	Asn	ı	
65					70					75			•		80		

Val Glu Leu Met Arg Asp Val Ser Lys Glu Asp His Ser Lys Arg Ser 100 105 110

Leu Lys Tyr Glu Val Arg Asn Lys Asn Asp Leu Thr Arg Glu Glu Ile

Ser Phe Val Cys Val Leu Leu Ser His Gly Glu Glu Gly Ile Ile Phe 115 120 125

Gly Thr Asn Gly Pro Val Asp Leu Lys Lys Ile Thr Asn Phe Phe Arg 130 135 140

Gly Asp Arg Cys Arg Ser Leu Thr Gly Lys Pro Lys Leu Phe Ile Ile 145 150 155 160

Gln Ala Cys Arg Gly Thr Glu Leu Asp Cys Gly Ile Glu Thr Asp Ser 165 170 175

Gly Val Asp Asp Met Ala Cys His Lys Ile Pro Val Asp Ala Asp
180 185 190

Phe Leu Tyr Ala Tyr Ser Thr Ala Pro Gly Tyr Tyr Ser Trp Arg Asn 195 200 205

Ser Lys Asp Gly Ser Trp Phe Ile Gln Ser Leu Cys Ala Met Leu Lys 210 215 220 . }

. ]

Gln Tyr Ala Asp Lys Leu Glu Phe Met His Ile Leu Thr Arg Val Asn 225 230 . 235 240

Arg Lys Val Ala Thr Glu Phe Glu Ser Phe Ser Phe Asp Ala Thr Phe 245 250 255

His Ala Lys Lys Gln Ile Pro Cys Ile Val Ser Met Leu Thr Lys Glu \$260\$ \$270\$

Leu Tyr Phe Tyr His 275

<210> 2.

<211> 6

<212> PRT

<213> Homo sapiens

<400> 2

Phe Ser Phe Asp Ala Thr

```
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> Granzyme B Mutation Forward Primer
<400> 3
ccagcgtata attctaagac agcctccaat gacatcatgc tg
                                                                   42
<210> 4
<211> 6
<212> PRT
<213> Homo sapiens
<400> 4
Ile Glu Thr Asp Ser Gly
<210> 5
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> Granzyme B Mutation Reverse Primer
<400> 5
cagcatgatg tcattggagg ctgtcttaga attatacgct gg
                                                                   42
<210> 6
<211> 6
<212> PRT
<213> Homo sapiens
<220>
<221> Variant
<222> (1)..(1)
<223> Wherein Xaa is an N-acetyl group.
<220>
<221> Variant
<222> (6)..(6)
<223> Wherein Xaa is a 7-amino-4-methylcoumarin group.
<400> 6
Xaa Ile Glu Pro Asp Xaa
```

.

. }

. 1

.'1

1

```
<211> 4
 <212> PRT
 <400> 7
 <210> 8
 <211> 4
 <212> PRT
 <210> 9
 <211> 4
 <212> PRT
 <400> 9
 <210> 10
 <211> 4
 <212> PRT
 <400> 10 ·
 <210> 11 .
 <211> 4
 <212> PRT
 <400> 11
```

```
<213> Homo sapiens
Ala Glu Ala Lys
<213> Homo sapiens
<400> 8
Glu Asn Val Lys
<213> Homo sapiens
Gly Thr Glu Asp
<213> Homo sapiens
Ser Pro Thr Arg
<213> Homo sapiens
Val Ser Thr Arg
<210> 12
<211> 4
<212> PRT
```

.)

```
<213> Homo sapiens
<400> 12
Ser Thr Ser Phe
<210> 13
<211> 4
<212> PRT
<213> Homo sapiens
<400>,13
Lys Phe Pro Asp
<210> 14
<211> 4
<212> PRT
<213> Homo sapiens
<400> 14
Ala Glu Gln Arg
1
<210> 15
<211> 4
<212> PRT
<213> Homo sapiens
<400> 15
Lys Tyr Ala Asp
<210> 16
<211> 4 .
<212> PRT
<213> Homo sapiens
<400> 16
Asn Gly Pro Lys
<210> 17
```

<211> 4 <212> PRT

<213> Homo sapiens

Ä.

. 1

. 1

```
<213> Homo sapiens
<400> 19
Ala Gln Glu Lys
1
<210> 20
<211> 4
<21.2> PRT
<213> Homo sapiens
<400> 20
Arg Ile Asp Tyr
<210> 21
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> IEPD
<400> 21
Ile Glu Pro Asp
<210> 22
<211> 4
<212> PRT
<213> Artificial Sequence
```

<400> 17

<210> 18 <211> 4 <212> PRT

<400> 18

<210> 19 <211> 4 <212> PRT

Gly Thr Ser Asp

Ser Ser Ala Tyr

<213> Homo sapiens

```
<220>
<223> Ac-DEVD-AMC fluorogenic substrate
<220>
<221> MOD_RES
<222> 1
<223> N-acetyl
<220>
<221> MOD_RES
<222> 4
<223> AMC
<400> 22
Asp Glu Val Asp
<210> 23
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> granzyme B substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Leu
<220>
<221> VARIANT
<222> 3
<223> Xaa = any amino acid
<400> 23
Xaa Glu Xaa Asp
1
<210> 24
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Granzyme A substrate specificity
<220>
<221> VARIANT
<222> i
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 2
```

r.

Υ.

Ġ.

.1

```
<223> Xaa= Ala or Gly
<220>
<221> VARIANT
<222> 3
<223> Xaa= Asn, Asp or Glu
<400> 24
Xaa Xaa Xaa Arg
<210> 25
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Cathepsin G substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa= Val or Leu
<220>
<221> VARIANT
<222> 4
<223> Xaa= Phe or Lys
<400> 25
Xaa Xaa Xaa Xaa
. 1
<210> 26
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> MTSP-1 substrate specificity
<220>
<221> VARIANT
<223> Xaa= Arg or any hydrophobic amino acid
```

ì

 $\mathcal{F}$ 

 $\cdot$ 

```
<220>
 <221> VARIANT
 <222> 2
 <223> Xaa= Arg or any hydrophobic amino acid
 <220>
 <221> VARIANT
 <222> 3
 <223> Xaa= Ser or Thr
 <220>
 <221> VARIANT
 <222> 4
 <223> Xaa= Arg or Lys
 <400> 26
 Xaa Xaa Xaa Xaa
 <210> 27
 <211> 4
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> Neutrophil Elastase substrate specificity
<220>
 <221> VARIANT
 <222> 1
 <223> Xaa= Arg, Met or Lys
<220>
 <221> VARIANT
 <222> 2
 <223> Xaa= Gln or Glu
 <220>
 <221> VARIANT
 <222> 3
 <223> Xaa= Pro or Ala
 <220>
 <221> VARIANT
 <222> 4
 <223> Xaa= Val, Ala or Ile
 <400> 27
 Xaa Xaa Xaa Xaa
```

<210> 28
<211> 4
<212> PRT

ï.

.1

, T. -

,"i

Ţ,

```
<213> Homo sapiens
<220>
<223> Chymase substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa= Glu or Ala
<220>
<221> VARIANT
<222> 3
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 4
<223> Xaa= Phe or Tyr
<400> 28
Xaa Xaa Xaa Xaa
<210> 29
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Chymotrypsin substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa= Val or Pro
<220>
<221> VARIANT
```

<222> 4

<223> Xaa= Phe ot Tyr

."

.1

.')

'n.

.1

```
<400> 29
Xaa Xaa Xaa Xaa
<210> 30
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Easter substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa = Ile or Val
<220>
<221> VARIANT
<222> 2
<223> Xaa = Glu or Ala
<221> VARIANT
<222> 3
<223> Xaa = Val or Leu
<400> 30
Xaa Xaa Xaa Arg
 1
<210> 31
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Factor Xa substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= any amino acid
<220> '
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<400> 31
Xaa Xaa Gly Arg
```

4

.1

.

.

.'!

```
<210> 32
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Plasma Kallikrein substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= any hydrophobic amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa= Phe or Tyr
<400> 32
Xaa Xaa Xaa Arg
1 .
<210> 33
<211> 4
<212> PRT
<213> Homo sapiens
<223> Plasmin substarte specificity
<220>
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa= Trp or Phe
<400> 33
Lys Xaa Xaa Lys
1
<210> 34
<211> 4
```

.1

, 1

 $\mathcal{A}$ 

.4

1,

<220>

<212> PRT

<213> Homo sapiens

```
<223> Thrombin substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= Phe or Leu
<220>
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<400> 34
Xaa Xaa Pro Arg
1
<210> 35
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> tPA substrate specificity
<220>
<221> VARIANT
<222> 1
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa= Thr or Ser
<220>
<221> VARIANT
<222> 3
<223> Xaa=Gly or Ser
<400> 35
Xaa Xaa Xaa Arg
1
<210> 36
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> uPA substrate specificity
<220>
<221> VARIANT
<222> 1
```

<223> Xaa= any amino acid

.``

 $\Gamma_{\bullet}$ 

```
<220>
<221> VARIANT
<222> 2
<223> Xaa= Thr or Ser
<220> .
<221> VARIANT
<222> 3
<223> Xaa= Ser or Ala
<400> 36
Xaa Xaa Xaa Arg
1
<210> 37
<211> 4
<212> PRT
<213> Homo sapiens
<223> 199F granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 3
<223> Xaa = any amino acid
<400> 37
Xaa Glu Xaa Asp
1 .
<210> 38
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> I99A granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Val
<400> 38
Xaa Glu Phe Asp
```

1

,';

,"

<u>,</u>'1

```
<210> 39
.<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> I99K granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 3
<223> Xaa= any amino acid
<400> 39
Xaa Glu Xaa Asp
<210> 40
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> N218A granzyme B substrate spec.
<220>
<221> VARIANT
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 2
<223> Xaa= any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa= any amino acid
<400> 40
Xaa Xaa Xaa Asp
```

<210> 41 <211> 4 <212> PRT

٠.

,4

```
<213> Homo sapiens
 <220>
 <223> N218T granzyme B substrate spec.
 <220>
 <221> VARIANT
 <222> 1
 <223> Xaa= Ile or val
 <220>
 <221> VARIANT
 <222> 2
 <223> Xaa= Ala or Ser
 <220>
 <221> VARIANT
 <222> 3
 <223> Xaa= any amino acid
 <400> 41
 Xaa Xaa Xaa Asp
 <210> 42
 <211> 4
 <212> PRT
 <213> Homo sapiens
. <220>
 <223> N218V granzyme B substrate spec.
 <220>
 <221> VARIANT
 <222> 1
 <223> Xaa=Ile or Val
 <220>
 <221> VARIANT
 <222> 2
 <223> Xaa=any amino acid
 <220>
 <221> VARIANT
 <222> 3
 <223> Xaa=any amino acid
 <400> 42
 Xaa Xaa Xaa Asp
```

.1

<210> 43 <211> 4

```
<212> PRT
<213> Homo sapiens
<220>
<223> R192A granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 3
<223> Xaa= any amino acid
<400> 43
Xaa Glu Xaa Asp
1
<210> 44
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> R192E granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 2
<223> Xaa= Lys, Gln or Ser
<220>
<221> VARIANT
<222> 3
<223> Xaa=any amino acid
<400> 44
Xaa Xaa Xaa Asp
<210> 45
<211> 4
<212> PRT
<213> Homo sapiens
```

.'i

.

. :

. `

<220>

```
<221> VARIANT
<222> 1
<223> Xaa= Ile Val or Leu
<220>
<221> VARIANT
<222> 3
<223> Xaa= any amino acid
<400> 45
Xaa Glu Xaa Asp
1
<210> 46
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Y174V granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa=Ile or Val
<220>
<221> VARIANT
<222> 3
<223> Xaa=any amino acid
<400> 46
Xaa Glu Xaa Asp
<210> 47
<211> 4
<212> PRT ,
<213> Homo sapiens
<220>
<223> I99A/N218A granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1 ·
<223> Xaa=Phe, Leu, Ile or Val
```

,;;

<223> Y174A granzyme B substrate spec.

<220>

<220>

```
<221> VARIANT
<222> 2
<223> Xaa= Ala or ser
<400> 47
Xaa Xaa Phe Asp
1
<210> 48
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> R192A/N218A granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 2
<223> Xaa= Ala, Gln or Ser
<220>
<221> VARIANT
<222> 3
<223> Xaa= any amino acid
<400> 48
Xaa Xaa Xaa Asp
<210> 49
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> R192E/N218A granzyme B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa= Ile or Val
<220>
<221> VARIANT
<222> 2
```

<223> Xaa= Arg, Lys or Ala

Α,

```
<220>
 <221> VARIANT
 <222> 3 ·
 <223> Xaa= any amino acid
 <400> 49
 Xaa Xaa Xaa Asp
 1
 <210> 50
 <211> 4
<212> PRT
 <213> Homo sapiens
 <220>
 <223> Cathepsin G substrate specificity
 <220>
 <221> VARIANT
 <222> 1
 <223> Xaa=any amino acid
 <220>
 <221> VARIANT
 <222> 2
 <223> Xaa=any amino acid
 <220>
 <221> VARIANT
 <222> 3
 <223> Xaa=Phe or Trp
 <220>
 <221> VARIANT
 <222> 4
 <223> Xaa=Arg or Lys
 <400> 50
Xaa Xaa Xaa Xaa
 <210> 51
 <211> 4
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> Cathepsin V substrate spec.
 <220>
 <221> VARIANT
```

<222> 1

<223> Xaa= any amino acid

, i

,;;

```
<220>
<221> VARIANT
<222> 2
<223> Xaa= Pro or any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa= Trp, Tyr or Phe
<220>
<221> VARIANT
<222> 4
<223> Xaa= any amino acid
<400> 51
Xaa Xaa Xaa Xaa
<210> 52
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Cathepsin K substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa=any amino acid
<220>
<221> VARIANT
<223> Xaa=any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa=Leu or Pro
<220>
<221> VARIANT
<222> 4
<223> Xaa=Arg or Lys
<400> 52
Xaa Xaa Xaa Xaa
```

;;

<210> 53 <211> 4

<212> PRT

```
<213> Homo sapiens
. <220>
<223> Cathepsin S substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa=any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa=Arg or any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa=Val, Leu or Met
<220>
<221> VARIANT
<222> 4
<223> Xaa=Lys.or Arg
<400> 53
Xaa Xaa Xaa Xaa
 1
<210> 54
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Cathepsin F substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa=any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa=any amino acid
<220>
<221> VARIANT
<222> 4
<223> Xaa=Lys or Arg
```

,;;

*:*:

;;

<400> 54 'Xaa Xaa Leu Xaa

```
<210> 55
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Cathepsin B substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa=any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa=Pro or any amino acid
<220>
<221> VARIANT
<222> 3
<223> Xaa=Val, Phe or Tyr
<220>
<221> VARIANT
<222> 4
<223> Xaa=Arg or Lys
<400> 55
Xaa Xaa Xaa Xaa
<210> 56
<211> 4
<212> PRT
<213> Homo sapiens
<220>
<223> Papain substrate spec.
<220>
<221> VARIANT
<222> 1
<223> Xaa=any amino acid
<220>
<221> VARIANT
<222> 2
<223> Xaa=Pro or any amino acid
```

<220>

, 77

,:

```
<221> VARIANT
```

<222> 3

<223> Xaa=Val, Phe or Tyr

<220>

<221> VARIANT

<222> 4

<223> Xaa=Arg or Lys

<400> 56

Xaa Xaa Xaa Xaa

1

<210> 57

<211> 4

<212> PRT

<213> Homo sapiens

<220>

<223> Cruzain substrate spec.

<

, '

1

·